Moderna Reports Narrower Q2 Net Loss but Norovirus Vaccine Fails Interim Analysis
Moderna reported a narrower second-quarter net loss of $782 million, or $1.97 per share, compared to the previous year's $825 million, or $2.13 per share. The results beat analysts' expectations who had forecasted a per-share loss of $2.03. However, Moderna announced that its norovirus vaccine candidate, mRNA-1403, did not meet statistical success criteria in an interim Phase 3 trial analysis. The company's stock dropped about 5.7% to $54.61 in premarket trading following the news. Despite this setback, Moderna highlighted strong financial execution and improved its 2026 operating expense outlook. Revenue for Q2 increased slightly to $145 million from a year ago due to deliveries under a U.K. government partnership offsetting lower sales of its COVID-19 vaccine in other regions.
Tickers: $MRNA
Topics: clinical_trials pharmaceuticals vaccines